Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 2.35 0.12 (5.38%) Market Cap: 12.72 Mil Enterprise Value: 13.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Q3 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $24.6 (+7.89%)
Operator

Greetings, and welcome to the BrainStorm Cell Therapeutics third-quarter 2022 conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

And now I would like to introduce your host for today's conference, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood
LifeSci Advisors - IR

Good morning and thank you for joining us. Before we begin the call and opening remarks, we'd like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance.

Statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot